Literature DB >> 23252824

Expression of HIV gp120 protein increases sensitivity to the rewarding properties of methamphetamine in mice.

James P Kesby1, David T Hubbard, Athina Markou, Svetlana Semenova.   

Abstract

Methamphetamine abuse and human immunodeficiency virus (HIV) infection induce neuropathological changes in corticolimbic brain areas involved in reward and cognitive function. Little is known about the combined effects of methamphetamine and HIV infection on cognitive and reward processes. The HIV/gp120 protein induces neurodegeneration in mice, similar to HIV-induced pathology in humans. We investigated the effects of gp120 expression on associative learning, preference for methamphetamine and non-drug reinforcers, and sensitivity to the conditioned rewarding properties of methamphetamine in transgenic (tg) mice expressing HIV/gp120 protein (gp120-tg). gp120-tg mice learned the operant response for food at the same rate as non-tg mice. In the two-bottle choice procedure with restricted access to drugs, gp120-tg mice exhibited greater preference for methamphetamine and saccharin than non-tg mice, whereas preference for quinine was similar between genotypes. Under conditions of unrestricted access to methamphetamine, the mice exhibited a decreased preference for increasing methamphetamine concentrations. However, male gp120-tg mice showed a decreased preference for methamphetamine at lower concentrations than non-tg male mice. gp120-tg mice developed methamphetamine-induced conditioned place preference at lower methamphetamine doses compared with non-tg mice. No differences in methamphetamine pharmacokinetics were found between genotypes. These results indicate that gp120-tg mice exhibit no deficits in associative learning or reward/motivational function for a natural reinforcer. Interestingly, gp120 expression resulted in increased preference for methamphetamine and a highly palatable non-drug reinforcer (saccharin) and increased sensitivity to methamphetamine-induced conditioned reward. These data suggest that HIV-positive individuals may have increased sensitivity to methamphetamine, leading to high methamphetamine abuse potential in this population.
© 2012 The Authors, Addiction Biology © 2012 Society for the Study of Addiction.

Entities:  

Keywords:  Conditioned place preference; food-maintained responding; oral self-administration; pharmacokinetics; quinine; saccharin

Mesh:

Substances:

Year:  2012        PMID: 23252824      PMCID: PMC3608835          DOI: 10.1111/adb.12023

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  68 in total

1.  Associations between methamphetamine use and HIV among men who have sex with men: a model for guiding public policy.

Authors:  Steven Shoptaw; Cathy J Reback
Journal:  J Urban Health       Date:  2006-11       Impact factor: 3.671

Review 2.  Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade.

Authors:  Thomas M Tzschentke
Journal:  Addict Biol       Date:  2007-09       Impact factor: 4.280

Review 3.  New insights into the mechanism of action of amphetamines.

Authors:  Annette E Fleckenstein; Trent J Volz; Evan L Riddle; James W Gibb; Glen R Hanson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

4.  Acquisition of i.v. cocaine self-administration in adolescent and adult male rats selectively bred for high and low saccharin intake.

Authors:  Jennifer L Perry; Marissa M Anderson; Sarah E Nelson; Marilyn E Carroll
Journal:  Physiol Behav       Date:  2007-02-12

5.  Repeated exposure to methamphetamine causes long-lasting presynaptic corticostriatal depression that is renormalized with drug readministration.

Authors:  Nigel S Bamford; Hui Zhang; John A Joyce; Christine A Scarlis; Whitney Hanan; Nan-Ping Wu; Véronique M André; Rachel Cohen; Carlos Cepeda; Michael S Levine; Erin Harleton; David Sulzer
Journal:  Neuron       Date:  2008-04-10       Impact factor: 17.173

6.  Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users.

Authors:  G Chana; I P Everall; L Crews; D Langford; A Adame; I Grant; M Cherner; D Lazzaretto; R Heaton; R Ellis; E Masliah
Journal:  Neurology       Date:  2006-10-24       Impact factor: 9.910

7.  Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse.

Authors:  Minoru Narita; Mayumi Miyatake; Michiko Narita; Masahiro Shibasaki; Keiko Shindo; Atsushi Nakamura; Naoko Kuzumaki; Yasuyuki Nagumo; Tsutomu Suzuki
Journal:  Neuropsychopharmacology       Date:  2006-01-11       Impact factor: 7.853

Review 8.  Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex.

Authors:  Satoshi Ikemoto
Journal:  Brain Res Rev       Date:  2007-05-17

Review 9.  The debate over dopamine's role in reward: the case for incentive salience.

Authors:  Kent C Berridge
Journal:  Psychopharmacology (Berl)       Date:  2006-10-27       Impact factor: 4.530

Review 10.  Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration.

Authors:  Shaji Theodore; Wayne A Cass; Avindra Nath; William F Maragos
Journal:  Curr HIV Res       Date:  2007-05       Impact factor: 1.581

View more
  17 in total

1.  HIV-1 TAT protein enhances sensitization to methamphetamine by affecting dopaminergic function.

Authors:  James P Kesby; Julia A Najera; Benedetto Romoli; Yiding Fang; Liana Basova; Amanda Birmingham; Maria Cecilia G Marcondes; Davide Dulcis; Svetlana Semenova
Journal:  Brain Behav Immun       Date:  2017-05-08       Impact factor: 7.217

Review 2.  Effects of HIV and Methamphetamine on Brain and Behavior: Evidence from Human Studies and Animal Models.

Authors:  Virawudh Soontornniyomkij; James P Kesby; Erin E Morgan; Amanda Bischoff-Grethe; Arpi Minassian; Gregory G Brown; Igor Grant
Journal:  J Neuroimmune Pharmacol       Date:  2016-08-02       Impact factor: 4.147

Review 3.  The HIV-1 transgenic rat model of neuroHIV.

Authors:  Michael Vigorito; Kaitlyn P Connaghan; Sulie L Chang
Journal:  Brain Behav Immun       Date:  2015-02-27       Impact factor: 7.217

4.  Cognitive deficits associated with combined HIV gp120 expression and chronic methamphetamine exposure in mice.

Authors:  James P Kesby; Athina Markou; Svetlana Semenova
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-04       Impact factor: 4.600

5.  Methamphetamine Exposure Combined with HIV-1 Disease or gp120 Expression: Comparison of Learning and Executive Functions in Humans and Mice.

Authors:  James P Kesby; Robert K Heaton; Jared W Young; Anya Umlauf; Steven P Woods; Scott L Letendre; Athina Markou; Igor Grant; Svetlana Semenova
Journal:  Neuropsychopharmacology       Date:  2015-02-05       Impact factor: 7.853

Review 6.  Methamphetamine and Cannabis: A Tale of Two Drugs and their Effects on HIV, Brain, and Behavior.

Authors:  Rowan Saloner; Jerel Adam Fields; Maria Cecilia Garibaldi Marcondes; Jennifer E Iudicello; Sofie von Känel; Mariana Cherner; Scott L Letendre; Marcus Kaul; Igor Grant
Journal:  J Neuroimmune Pharmacol       Date:  2020-09-15       Impact factor: 4.147

7.  Psychostimulant Abuse and HIV Infection: cocaine, methamphetamine, and "bath salts" cathinone analogues.

Authors:  Brenda M Gannon; Emily E Reichard; William E Fantegrossi
Journal:  Curr Addict Rep       Date:  2014-09-01

Review 8.  Transgenic mice expressing HIV-1 envelope protein gp120 in the brain as an animal model in neuroAIDS research.

Authors:  Victoria E Thaney; Ana B Sanchez; Jerel A Fields; Arpi Minassian; Jared W Young; Ricky Maung; Marcus Kaul
Journal:  J Neurovirol       Date:  2017-10-26       Impact factor: 2.643

9.  Combination of methamphetamine and HIV-1 gp120 causes distinct long-term alterations of behavior, gene expression, and injury in the central nervous system.

Authors:  Melanie M Hoefer; Ana B Sanchez; Ricky Maung; Cyrus M de Rozieres; Irene C Catalan; Cari C Dowling; Victoria E Thaney; Juan Piña-Crespo; Dongxian Zhang; Amanda J Roberts; Marcus Kaul
Journal:  Exp Neurol       Date:  2014-09-20       Impact factor: 5.330

10.  The effects of HIV-1 regulatory TAT protein expression on brain reward function, response to psychostimulants and delay-dependent memory in mice.

Authors:  James P Kesby; Athina Markou; Svetlana Semenova
Journal:  Neuropharmacology       Date:  2016-06-15       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.